Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pharvaris BV (PHVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PHVS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $33.88
1 Year Target Price $33.88
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 45.96% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.48B USD | Price to earnings Ratio - | 1Y Target Price 33.88 |
Price to earnings Ratio - | 1Y Target Price 33.88 | ||
Volume (30-day avg) 9 | Beta -2.81 | 52 Weeks Range 11.51 - 26.33 | Updated Date 08/15/2025 |
52 Weeks Range 11.51 - 26.33 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.61 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.7686 | Actual -0.83 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.85% | Return on Equity (TTM) -65.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1245248905 | Price to Sales(TTM) - |
Enterprise Value 1245248905 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 64299500 | Shares Floating 37146213 |
Shares Outstanding 64299500 | Shares Floating 37146213 | ||
Percent Insiders 5.32 | Percent Institutions 76.25 |
Upturn AI SWOT
Pharvaris BV
Company Overview
History and Background
Pharvaris BV is a late-stage clinical biotechnology company focused on discovering and developing oral small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE). Founded in 2015, Pharvaris has advanced clinical development through several phases and recently faced FDA challenges concerning a clinical trial.
Core Business Areas
- Hereditary Angioedema (HAE) Therapeutics: Development and commercialization of oral bradykinin-B2-receptor antagonists for acute and prophylactic treatment of HAE.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientific advisors with expertise in drug development and commercialization. The organizational structure involves research, clinical development, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Deucrictibant (PHA121): An oral, on-demand therapy under development for acute HAE attacks. The competitors in this market are BioCryst Pharmaceuticals (ORLADEYO, an oral prophylactic treatment), Takeda (TAKHYZRO, a subcutaneous prophylactic treatment and FIRAZYR, a subcutaneous on-demand treatment), and CSL Behring (HAEGARDA, a subcutaneous prophylactic treatment and BERINERT, an intravenous on-demand treatment). Currently, Deucrictibant has no market share as it is still in clinical trials. However, it targets the on-demand treatment market segment.
- PHA121 Prophylaxis: Oral prophylactic option for HAE. No market share data currently available as it is in development. Competitors would be the same as above for ORLADEYO, TAKHYZRO and HAEGARDA.
Market Dynamics
Industry Overview
The HAE market is characterized by high unmet needs for convenient and effective treatments. The market is driven by increasing awareness, improved diagnosis, and the development of novel therapies.
Positioning
Pharvaris aims to capture a significant share of the HAE treatment market by offering convenient oral therapies. The main competitive advantage is the anticipated oral route of administration for both acute and prophylactic treatment, pending regulatory approval.
Total Addressable Market (TAM)
The global HAE market is estimated at several billion USD and is projected to continue growing. Pharvaris is positioned to address a significant portion of this TAM with its oral therapies, specifically in the acute treatment setting.
Upturn SWOT Analysis
Strengths
- Oral formulation (potential)
- Novel mechanism of action
- Strong intellectual property position
- Experienced management team
Weaknesses
- Single product focus
- Reliance on clinical trial success
- Limited commercial infrastructure
- Regulatory approval risk
Opportunities
- Expanding HAE treatment market
- Potential for orphan drug designation
- Partnerships with larger pharmaceutical companies
- Geographic expansion
Threats
- Competition from existing HAE therapies
- Clinical trial failures
- Regulatory hurdles
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- BCRX
- TAK
- CSL
Competitive Landscape
Pharvaris's competitive advantage lies in the oral route of administration. However, the company faces significant competition from established players with approved therapies and strong market presence.
Growth Trajectory and Initiatives
Historical Growth: Growth has been focused on advancing clinical trials and securing financing.
Future Projections: Future growth hinges on successful completion of clinical trials and regulatory approval of Deucrictibant and the prophylactic therapy. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing clinical trials, addressing FDA concerns and exploring potential partnerships.
Summary
Pharvaris is a promising clinical-stage company with a focus on oral HAE therapies. Its success depends heavily on the successful completion of clinical trials and regulatory approval. The company faces strong competition, but its oral treatment option could be a significant differentiator. However, failure to achieve positive clinical outcomes and regulatory approval, or a competitor getting to market first, are considerable risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Actual results may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharvaris BV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-02-05 | Co-Founder, CEO & Executive Director Mr. Berndt Axel Edvard Modig CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 119 | Website https://pharvaris.com |
Full time employees 119 | Website https://pharvaris.com | ||
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.